In Part I, I mapped the highway from first assay hit to FDA approval. But an equal amount of science, strategy and regulatory chess unfolds after the Phase 3 data lock. This instalment unpacks five things every scientist-investor should master:

1. Advisory-committee (AdComm) hearings

2. Complete Response Letters (CRLs) & resubmissions

3. Label negotiations, REMS and supplemental filings

4. Post-marketing requirements/commitments (PMRs/PMCs)

5. Pharmacovigilance: FAERS, Sentinel & real-world evidence

1 · Advisory Committees—The Public Stress-Test

What they are. FDA convenes > 30 standing committees of outside experts who review select NDAs/BLAs. The meeting is public; slides, briefing books and a webcast go live two days beforehand.

When they’re triggered. High-novelty targets, marginal benefit-risk, or intense public interest (e.g., psychedelic psychiatry) almost always see an AdComm.

Voting mechanics. After sponsor & FDA presentations, panellists vote “Yes/No/Abstain” on efficacy, safety and approvability. Though non-binding, FDA sides with the vote ≈ 80 % of the time.

Recent trend. Vacancies rose from 21 % (FY-23) to 28 % (FY-24) as academics cite workload and social-media backlash for declining invitations. FDA is piloting shorter terms and virtual testimony to plug those gaps.

Case in point. Aduhelm (aducanumab) famously received 10–0 “No” on evidence of efficacy yet was approved under Accelerated Approval, sparking the current debate on AdComm reform.

2 · Complete Response Letters—“Not Yet, Here’s Why”

If the agency cannot approve an application in its present form, it issues a Complete Response Letter (CRL) under 21 CFR 314.110 (drugs) or 601.3 (biologics). Key attributes:

Transparency leap. In July 2025 FDA published > 200 redacted CRLs from 2020-2024, citing a “radical transparency” pledge. Analysis shows companies publicly disclosed only 14 % of the cited deficiencies, a reminder to investors that sponsor press releases can be selective.

3 · Label, REMS & the Supplemental Game

Label negotiations. Even approvals morph during the final weeks: FDA wordsmiths indications, contraindications, and data tables. Label scope can dictate market size more than P-value.

Risk Evaluation and Mitigation Strategy (REMS). ~ 20 % of NMEs launch with a REMS—elements range from medication guides to restricted-dispensing programs (e.g., isotretinoin’s iPLEDGE). REMS modifications require supplemental submissions.

Life-cycle filings. Post-approval changes travel through sNDA/sBLA pathways:

Knowing these lanes helps teams time follow-on trials and investors model cash-flow inflections.

4 · Post-Marketing Requirements & Commitments (PMRs / PMCs)

FDA can impose legally binding PMRs under four statutes (Pediatric Research Equity Act, Accelerated Approval, etc.). As of July 2025 the public database lists ≈ 1 100 open PMRs/PMCs; ~ 38 % are Phase 4 efficacy studies.

Failure to deliver can lead to label restrictions or rare withdrawals.

5 · Pharmacovigilance in the Real World

5.1 FAERS 2.0

The FDA Adverse Event Reporting System now hosts a self-service dashboard (v2.0) with quarterly data cuts, updated FAQs and API endpoints.

5.2 Sentinel Initiative

A distributed network (> 100 M covered lives) pulls EHR, claims and registry data to run rapid safety queries (propensity-matched cohorts, sequential monitoring). Sentinel executed > 600 signal evaluations between 2008-2024, leading to label changes for JAK inhibitors and SGLT2s.

5.3 Real-world evidence (RWE) guidances

Draft guidances (2023-2024) clarify when RWE can support supplemental indications or satisfy PMRs, provided data are “fit-for-purpose” and analyses pre-specified.

Metrics at a Glance (2020-2024)

*CRL counts from public statements + newly released archive; precise totals may shift as FDA releases more letters.
(Note: 2024 REMS figure via internal FDA REMS@FDA tracker.)

Key Take-aways

• AdComms are rare but market-moving; read both sponsor & FDA briefing books.

• A CRL is a delay, not a death sentence— 60 % of resubmissions eventually win approval.

• Label language ≥ headline indication. Physicians and payers scrutinise restrictions.

• Post-marketing work never ends. PMRs, REMS, Sentinel and FAERS can reshape a product’s trajectory years after launch.

Further Reading & Tools

• FDA, Guidance: Advisory Committee Procedures (2024 revision)

• FDA, MAPP 6020.4 Rev. 1 – Complete Response Letter Policy (2025)

• FDA, Postmarketing Requirements & Commitments Database (interactive) U.S. Food and Drug Administration

• Sentinel Initiative, Annual Report 2024 Sentinel Initiative

• Sacks et al., “Scientific and Regulatory Reasons for Drug Approval and Disapproval” NEJM 2022

• Podcast: “Pink Sheet – CRL Deep Dive” (June 2025 episode)

1. Small Molecules vs. Biologics – Know Your Beast

2. Eight Milestones on the Road to Market

*The “clock” starts 60 days after the application lands at FDA.

3. PDUFA – the Deadlines That Matter

Congress first authorized the Prescription Drug User Fee Act (PDUFA) in 1992, letting FDA collect industry fees in exchange for predictable review timelines. We are currently in PDUFA VII (2023-2027), which binds FDA to meet its 6- or 10-month goals on ≥ 90 % of files. Failure is rare – FDA has hit the mark ~97 % of the time since PDUFA VI.

4. Four Expedited Pathways (Don’t Confuse Them!)

All four programs can stack (e.g., Breakthrough + Priority). FDA’s 2024 guidance summarises criteria and obligations.

5. How Many Novel Drugs Actually Win?

• 2024: CDER cleared 50 novel NMEs/biologics – roughly the decade average.

• First-in-class share: Historically 30-40 % of those approvals carry novel targets, underscoring FDA’s receptiveness to innovation.

• Success rate from Phase 1 ➔ approval: ~8-12 % (varies by therapy area).

6. Beyond Approval – Why Phase 4 Isn’t Optional

Even after a green light, FDA can mandate post-marketing requirements (PMRs) such as pediatric studies, cardiovascular-outcome trials, or confirmatory trials for accelerated approvals. Failure to deliver can trigger label restrictions or withdrawal.

7. Key Take-aways for Investors & Founders

1. Know your filing lane. NDA vs BLA dictates review center, user fees, and manufacturing expectations.

2. Exploit accelerated paths — but respect the fine print. Breakthrough saves time only if you can feed FDA high-quality data quickly.

3. CMC can kill you late. Many biologics stumble not on efficacy but on manufacturing comparability.

4. PDUFA date = liquidity event. For public companies, the stock often moves most at acceptance (day 0) and at approval/CRL (day PDUFA).

Further Reading & Resources

• FDA, Expedited Programs for Serious Conditions – Drugs and Biologics (Guidance, 2023) U.S. Food and Drug Administration

• FDA, Advancing Health Through Innovation: New Drug Therapy Approvals 2024 (Annual report) U.S. Food and Drug Administration

• FDA, Prescription Drug User Fee Act (PDUFA VII) Performance Goals (2022-2027) U.S. Food and Drug Administration

• FDA, Investigational New Drug Applications for CBER-Regulated Products (2025 update) U.S. Food and Drug Administration

• Pink Sheet podcast – “How to Think About Accelerated Approval in 2025” (audio)

• Book: Bennett & Lasky, “FDA Regulatory Affairs: A Guide for Prescription Drugs, Medical Devices, and Biologics” (Fourth Ed., 2023)